Pazopanib maintenance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma

[1]  S. Iida,et al.  The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib , 2018, Internal medicine.

[2]  U. Dirksen,et al.  Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow , 2016, Oncotarget.

[3]  U. Dirksen,et al.  Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Alcindor.  Response of refractory Ewing sarcoma to pazopanib , 2015, Acta oncologica.

[5]  C. Dufour,et al.  Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults , 2015, Bone Marrow Transplantation.

[6]  Robin L. Jones,et al.  Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma , 2015, Rare tumors.

[7]  Yutaka Yamamoto,et al.  Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum , 2014, International journal of urology.

[8]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[9]  U. Popat,et al.  Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma , 2011, Bone Marrow Transplantation.

[10]  U. Dirksen,et al.  Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Wexler,et al.  Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan‐Kettering experience , 2009, Pediatric blood & cancer.

[12]  M. Burke,et al.  Tandem high‐dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high‐risk Ewing family tumors , 2007, Pediatric blood & cancer.

[13]  A. Craft,et al.  Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO‐E.W.I.N.G. 99 clinical trial , 2006, Pediatric blood & cancer.

[14]  J. Wharton,et al.  High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. , 2001, Gynecologic oncology.

[15]  W. Winkelmann,et al.  Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.